Relation between treatment efficacy and cumulative dose of alpha interferon in chronic hepatitis B

Journal of Hepatology

Volumn 25, Issue 6, 1996, Pages 795-802

  Krogsgaard, Kim ^c   Christensen, Erik ^d   Bindslev, Niels ^d   Schalm, Solko ^b   Andersen, Per Kragh ^a   Ring Larsen, Helmer ^d  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c The Capital Region   (Denmark)

^d NONE

Author keywords

Chronic hepatitis B; Cox regression analysis; Interferon treatment; Meta analysis; Randomized clinical trials; Time dependent covariates

Indexed keywords

ALPHA INTERFERON; HEPATITIS B CORE ANTIGEN; HEPATITIS B(E) ANTIGEN;

ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; DRUG EFFICACY; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REGRESSION ANALYSIS; SEROCONVERSION; TIME; TREATMENT OUTCOME;

EID: 0030472814     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(96)80281-9     Document Type: Article

References (23)

1. 1. Lok ASF, Weller IVD, Karayiannis P, Brown D, Fowler MJF, Monjardino J, Thomas HC, Sherlock S. Thrice weekly lymphoblastoid interferon is effective in inhibiting hepatitis B virus replication. Liver 1984; 4: 45-9.
2. 2. Hoofnagle JH, Peters M, Mullen KD, Brian Jones D, Rustgi V, Di Bisceglie A, Hallahan C, Park Y, Meschievitz C, Anthony Jones E. Randomized, controlled trial of recombinant human alpha interferon in patients with chronic hepatitis B. Gastroenterology 1988; 95: 1318-25.
3. 3. Brook MG, McDonald JA, Karayiannis P, Caruso L, Forster G, Harris JRW, Thomas HC. Randomised controlled trial of interferon alpha 2A (rbe) (Roferon-A) for the treatment of chronic hepatitis B virus (HBV) infection: factors that influence response. Gut 1989; 30: 1116-22.
4. 4. Perrillo RP, Schiff ER, Davis GL, Bodenheimer HC, Lindsay K, Payne J, Dienstag JL, O'Brien C, Tamburro C, Jacobson IM, Sampliner R, Feit D, Lefkowitch J, Kuhns M, Meschievitz C, Sanghvi B, Albrecht J, Gibas A, Hepatitis Interventional Therapy Group. A randomized, controlled trial of interferon alpha 2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990; 323: 295-301.
5. 5. Korenman J, Baker B, Waggoner J, Everhart JE, Di Bisceglie AM, Hoofnagle JH. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 1991; 114:629-34.
6. 6. Wong DKH, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993; 119: 312-23.
7. 7. Tine F, Liberati A, Craxi A, Almasio P, Pagliaro L. Interferon treatment in patients with chronic hepatitis B: a meta-analysis of the published literature. J Hepatol 1993; 18: 154-62.
8. 8. Krogsgaard K, Bindslev N, Christensen E, Craxi A, Schlichting P, Schalm S, Carreno V, Trepo C, Gerken G, Thomas HC, Kragh Andersen P, Ring-Larsen H, European Concerted Action on Viral Hepatitis. The treatment effect of alpha interferon in chronic hepatitis B is independent of pre-treatment variables. Results based on individual patient data from 10 clinical controlled trials. J Hepatol 1994; 21: 646-55.
9. 9. Alexander GJ, Brahm J, Pagan EA, Smith HM, Daniels HM, Eddleston AL, Williams R. Loss of HBsAg with interferon therapy in chronic hepatitis B virus infection. Lancet 1987; 2: 66-9.
10. 10. Franco A, Barnaba V, Levreno M, Ruberti G, Van Dyke A, Bonavita MS, Balsano F. Effect of 28 consecutive days lymphoblastoid interferon (alpha-IFN) administration on hepatitis B virus related chronic liver disease. J Hepatol 1986; 3 S2: s239-43.
11. 11. Saracco G, Mazella G, Rosina F, Cancellieri C, Lattore V, Raise E, Rocca G, Giorda L, Verme G, Gasbarrini G, Barbara L, Bonino F, Rizzetto M, Roda E. A controlled trial of human lymhoblastoid interferon in chronic hepatitis B in Italy. Hepatology 1989; 10: 336-41.
12. 12. Realdi G, Fattovich G, Pastore G, Carredda F, Noventa F, Santantonio T, Moroni M, Criscuolo D, Maladorno D, Rugge M, Dienes HP. Problems in the management of chronic hepatitis B with interferon: experience in a randomized, multicentre study. J Hepatol 1990; 11 S1: S129-32.
13. 13. Fevery J, Elewaut A, Michielsen P, Nevens F, Van Eyken P. Adler M, Desmet V. Efficacy of interferon alpha-2b with or without prednisone withdrawal in the treatment of chronic viral hepatitis B. A prospective double-blind Belgian-Dutch study. J Hepatol 1990; 11 S1: S108-12.
14. 14. Brook MG, Chan, G, Yap I, Karayiannis P, Lever AML, Jacyna M, Main J, Thomas HC. Randomised controlled trial of lymphoblastoid interferon alpha in Europid men with chronic hepatitis B virus infection. BMJ 1989; 199: 652-6.
15. 15. Lok, ASF, Novick DM, Karayiannis P, Dunk AA, Sherlock S, Thomas HC. A randomized study of the effects of adenine arabinoside 5′-monophosphate (short or long courses) and lymphoblastoid interferon on hepatitis B virus replication. Hepatology 1985; 6: 1132-8.
16. 16. Scully LJ, Shein R, Karayiannis P, McDonald JA, Thomas HC. Lymphoblastoid interferon therapy of chronic HBV infection, A comparison of 12 vs. 24 weeks of thrice weekly treatment. J Hepatol 1987; 5: 51-8.
17. 17. Thomas HC, Lok ASF, Carreno V, Farrell G, Tanno H, Perez V, Dusheiko GM, Cooksley G, Ryff JC, International Hepatitis Trial Group. Comparative study of three doses of interferon-(2a in chronic active hepatitis B. J Viral Hepatitis 1994; 1: 139-48.
18. 18. Christensen E. Multivariate survival analysis using Cox's regression model. Hepatology 1987; 7: 1346-58.
19. 19. Christensen E, Altman DG, Neuberger J, de Stavola BL, Tygstrup N, Williams R. Updating prognosis in primary biliary cirrhosis using a time-dependent Cox regression model. Gastroenterology 1993; 105: 1865-76.
20. 20. McDonald JA, Caruso L, Karayiannis P, Scully LJ, Harris JRW, Forster GE, Thomas HC. et al. Diminished responsiveness of male homosexual chronic hepatitis B virus carriers with HTLV-III antibodies to recombinant alpha-interferon. Hepatology 1987; 7: 719-23.
21. 21. Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology 1989; 10: 761-3.
22. 22. Perrillo RP. Factors influencing response to interferon in chronic hepatitis B: implications for asian and western populations. Hepatology 1990; 12: 1433-5.
23. 23, Thomas HC, Scully LJ, Lever AML, Yap I, Pignatelli M. A review of the efficacy of adenine arabinoside and lymphoblastoid interferon in the Royal Free Hospital studies of hepatitis B virus carrier treatment: identification of factors influencing response rates. Infection 1987; 15: S26-31.